All Oncology News

Disparities in Research Funding Exacerbate Cancer Incidence and Mortality

June 21st 2022

Suneel Kamath, MD, discusses the findings from research he conducted evaluating the effect of financial and racial disparities on cancer incidence and mortality.

Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS Benefit in Newly Diagnosed MCL

June 21st 2022

Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.

Guadecitabine Fails to Improve OS Over Physician’s Choice of Treatment in MDS and CMML

June 21st 2022

Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.

FDA Grants Orphan Drug Designation to PT217 for SCLC

June 21st 2022

The FDA has granted an orphan drug designation to PT217 for use as a potential therapeutic option for patients with small cell lung cancer.

Florida Cancer Specialists & Research Institute Expands Care With New Cancer Center Location in Lee County

June 21st 2022

Florida Cancer Specialists & Research Institute, LLC has opened a new state-of-the-art facility at 8981 Colonial Center Drive in Fort Myers to provide comprehensive treatments and a variety of services to adults with cancer and other diseases.

Media Plugin test

June 21st 2022

Radioligand Therapy Boosts Survival in mCRPC

June 21st 2022

The prostate specific membrane antigen-targeting therapy, lutetium Lu 177 vipivotide tetraxetan, was approved by the FDA for patients with metastatic castration-resistant prostate cancer in March.

Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer

June 21st 2022

The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.

FDA Grants Orphan Drug Designation to Paxalisib for Atypical Rhabdoid, Teratoid Tumors

June 20th 2022

The FDA has granted an orphan drug designation to paxalisib for use as a potential therapeutic option for patients with atypical rhabdoid and teratoid tumors, a rare and highly aggressive pediatric brain cancer.

Nemtabrutinib Generates Responses, Displays Manageable Safety in CLL/SLL

June 20th 2022

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Cilta-cel Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

June 20th 2022

A single infusion of the CAR T-cell therapy ciltacabtagene autoleucel produced deep and durable responses in patients with relapsed/refractory multiple myeloma with a manageable toxicity profile, according to long-term follow-up data of the phase 1b/2 CARTITUDE-1 trial.

Trastuzumab Deruxtecan Elicits Statistically Significant PFS in HR-Positive/HER2-Low Breast Cancer

June 20th 2022

Fam-trastuzumab deruxtecan-nxki demonstrated a statistically significant benefit in progression-free survival in patients with HER2-low metastatic breast cancer, meeting the primary end point of the phase 3 DESTINY-Breast04 trial and changing the standard of care for this patient population.

Yale Research Reveals “Biologically Older” Tissue in Patients with Breast Cancer

June 20th 2022

An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.

European Medicines Agency Validates Type II Variation Application for Liso-cel in Second-line LBCL

June 20th 2022

The European Medicines Agency has verified its type II variation application to extend the indication for lisocabtagene maraleucel to include the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for hematopoietic stem cell transplant.

A Molecular Revolution Is Underway in Thoracic Oncology

June 20th 2022

Targetable alterations including BRAF V600E, EGFR exon 20 insertions, KRAS G12C mutations, MET exon 14 alterations, NTRK and RET rearrangements have taken up recent focus for investigators as data are pushing novel agents through the regulatory processes.

T-VEC Plus Pembrolizumab Generates Promising Responses, Safety in PD-1–Refractory Advanced Melanoma

June 20th 2022

Adding talimogene laherparepvec to pembrolizumab led to encouraging responses with a manageable safety profile in patients with advanced melanoma who progressed on prior anti–PD-1 therapy, most notably in the adjuvant setting, according to findings from the phase 2 MASTERKEY-115 trial.

Markman Highlights Key Areas of Investigation in Oncology

June 19th 2022

Maurie Markman, MD, offers expert insights on the hurdles facing community oncologists, the uptake of biomarkers in the clinic, and an overview of what to look forward to in his area of expertise: gynecologic oncology.

Maintenance Cabozantinib/Avelumab Combo Under Investigation in Metastatic Urothelial Cancer

June 18th 2022

The addition of cabozantinib to avelumab is under exploration as a maintenance approach in patients with metastatic urothelial cancer following first-line, platinum-based chemotherapy.

Repotrectinib Receives Breakthrough Therapy Designations in China for ROS1+ NSCLC

June 17th 2022

The China National Medical Products Administration’s Center for Drug Evaluation granted 2 breakthrough therapy designations to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer.

FDA Grants Fast Track Designation to Dianhydrogalactitol for Newly Diagnosed Glioblastoma

June 17th 2022

The FDA has granted a fast track designation to dianhydrogalactitol for the treatment of patients with newly-diagnosed unmethylated glioblastoma.